Rhopressa Rocket 4 Phase 3 Results - Aerie Pharmaceuticals

Aerie Pharmaceuticals announced that Rhopressa (netarsudil) achieved its primary efficacy endpoint in the Phase 3 Rocket 4 trial, meeting non-inferiority to timolol BID for intraocular pressure reduction. The once-daily treatment demonstrated stable efficacy and a favorable safety profile, with conjunctival hyperemia as the main adverse event.